Straits Times Index
3,356.91 +18.34 (+0.55%) Nikkei
39,807.32 +176.26 (+0.44%) Hang Seng
17,952.25 +233.64 (+1.32%) FTSE 100
8,166.76 +2.64 (+0.03%) Bitcoin USD
62,961.01 -393.43 (-0.62%) CMC Crypto 200
1,345.25 +43.18 (+3.32%)
RANI Jul 2024 2.500 put
| Previous close | 0.3000 |
| Open | 0.3000 |
| Bid | 0.0000 |
| Ask | 0.5500 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.3000 - 0.3000 |
| Contract range | N/A |
| Volume | |
| Open interest | 33 |
GlobeNewswireRani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and ProGen to share responsibilities for the development and commercialization of RT-114, including a 50/50 cost and revenue share arrangement ~ ~ Rani to host conference call today at 8:00 a.m. ET/5:00 a.m. PT ~ SAN JOSE, Calif., June
- GlobeNewswire
Rani Therapeutics to Participate in May Investor Conferences
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the Company will participate in two upcoming investor conferences in May 2024. These conferences include: H.C. Wainwright 2nd Annual BioConnect Investor ConferenceLocation: The Nasdaq Headquarters, New York CityDate: Monday, May 20th at 2:30pm E.TFormat
- GlobeNewswire
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill® capsule, the company’s oral delivery platform, at Digestive Disease Week® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC. Details of the presentatio
